Our Platform
Thymus-targeted bifunctional antibodies
We are pioneering the development of thymus-targeted, bifunctional antibodies to induce central tolerance and address a broad range of autoimmune diseases. Achieving central tolerance has long been a major therapeutic goal, offering the potential for disease-modifying therapies for autoimmune diseases without the limitations of conventional immunosuppressive therapies and emerging approaches.
For the first time,
antibodies directed to the thymus
Our foundational insights into thymic biology have led to the development of the first systemically administered therapeutics designed to deliver self-antigens directly to thymic antigen-presenting cells (APCs). This approach promotes the development of tolerogenic regulatory T cells (Tregs) and the elimination of autoreactive conventional T cells. Our antibodies are specifically engineered for efficient thymic targeting, precise antigen presentation, and robust therapeutic activity.
Thymus-targeting element consists of a unique antibody variable domain that targets thymic antigen-presenting cells
Engineered Fc region enhances the therapeutic effect of the bifunctional antibody
Peripheral antigen is recombinantly fused to antibody scaffold for delivery to thymus to induce central tolerance
A highly differentiated therapeutic solution
By harnessing the natural mechanism of central tolerance, our bifunctional antibody therapies induce the generation of antigen-specific regulatory T cells (Tregs) providing a differentiated path to address autoimmunity.
Precise and potent
Antigen-specific Tregs uniquely suppress pathogenic immune responses at the site of autoantigen expression, providing potent, targeted therapy for autoimmune disease without the broad immunosuppression seen with peripherally expanded Tregs or cytokine therapies.
Durable and redosable
Thymus-derived Tregs exhibit epigenetic stability, ensuring long-term lineage commitment and reliable immune regulation. Our therapies are engineered for repeat dosing, enabling sustained modulation of autoimmunity and adaptable treatment over the course of disease.
Manufacturability
Our antibody therapies are off-the-shelf, enabling scalable, consistent, and readily available treatment while avoiding complex custom manufacturing.
Extended therapeutic reach
Thymus-derived Tregs are uniquely capable of homing to affected tissues and inducing tolerance through both antigen-specific and non-antigen specific mechanisms (bystander suppression). These broad effects enable our antibody therapies to address the many autoimmune diseases that involve multiple – or even unknown – autoantigens.
